Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 964 participants.

Also called NCT01042977

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 964 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01042977
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Austria, Bulgaria, Canada, Chile, Germany, Hungary, Poland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01042977. Randomized; quadruple masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2011-05 (actual). Results posted on 2013-08-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease
Condition
Type 2 Diabetes Mellitus
Condition
Cardiovascular Disease
Condition
Inadequate Glycaemic Control
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)
Collaborator
Bristol-Myers Squibb (class: industry)

Record details

Record id
cardio:ct-nct01042977
Content hash
609f13079d2778ce5959ec2fb0a8096cba7239f57c06bbf801349215b61c2c92